Financial Times: Analysts say Pfizer moving too slow on M&AFebruary 20, 2023 - " Most analysts have praised Pfizer’s selection of acquisitions but some say it is moving too slowly on M&A, given that it still needs to buy companies capable of generating an extra $15bn in annual revenues by 2030 to meet its growth targets.
“Pfizer has a lot of capacity to act, we estimate above $100bn. But they only did a couple of deals last year. That is not enough to move the needle,” said Seigerman."
David M. Denton, an experienced dealmaker brought on by Pfizer in 2022 said the company could spend an "extra" US$50 Bln to acquire the revenue goals that Pfizer et for 2030.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-names-david-m-denton-chief-financial-officer
"Les Funtleyder, a healthcare portfolio manager at E Squared Capital Management, said he expected Pfizer would make a series of acquisitions this year. These would likely focus on companies that are typically $10bn or below with products close to being commercialised, he said."
https://www.ft.com/content/ba2cba41-0a13-4251-bbd7-2abeff90433f